Factors Affecting Second-Line Therapy Choices in HCC

November 9, 2019
Wasif M. Saif, MD

Wasif M. Saif, MD, discusses available novel therapies for hepatocelluclar carcinoma.

Wasif M. Saif, MD, deputy physician in chief at Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses available novel therapies for treating hepatocelluclar carcinoma (HCC) in the second-line setting.

HCC is a heterogenous disease and difficult to treat, according to Saif, but there are now multiple agents available to treat patients who have failed first-line therapy, including 3 targeted agents—regorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza)—and 2 immunotherapy agents — nivolumab (Opdivo) and pembrolizumab (Keytruda). However, there are no randomized data to inform oncologists which patient is right for each agent.